Micronoma is a groundbreaking brand in the field of oncology, dedicated to pushing the boundaries of cancer detection. Through their innovative Oncobiota™ Platform, Micronoma challenges conventional wisdom by exploring the role of the microbiome in cancer. They believe that since our bodies evolved in a microbial world, cancer cells must coexist with microbes.

Leveraging state-of-the-art technology such as next-generation sequencing and AI, Micronoma has developed a microbiome-driven liquid biopsy. Recognized by the FDA with Breakthrough Designation Device status for lung carcinoma detection, this non-invasive test detects microbial signatures in the blood originating from the cancer microbiome. By enabling early-stage cancer detection and providing a less invasive alternative to diagnose benign or cancerous nodules, Micronoma aims to revolutionize how we view and tackle cancer.

With their multidisciplinary team and cutting-edge approach, Micronoma is committed to bringing us closer to a world where cancer is detected and defeated sooner